The Coviral Portal: Multi-Cohort Viral Loads and Antigen-Test Virtual Trials for COVID-19

3 Alexandra Morgan,¹ Elisa Contreras, ¹ Michie Yasuda, ¹ Sanjucta Dutta, ¹ Donald Hamel,³ Tarini

4 Shankar,^{1,4} Diane Balallo,^{1,5} Stefan Riedel,^{1,2} James E. Kirby,^{1,2} Phyllis J. Kanki,³ and Ramy

Arnaout^{1,2,6}†*

- 6 ¹Beth Israel Deaconess Medical Center, Division of Clinical Pathology, Department of Pathology,
- 7 Boston, MA 02215, USA; ²Harvard Medical School, Boston, MA 02215, USA; ³Harvard T.H. Chan
- 8 School of Public Health, Boston, MA 02215, USA; ⁴Northeastern University, Boston, MA 02215,
- 9 USA; ⁵Boston College, Chestnut Hill, MA 02467, USA; ⁶Beth Israel Deaconess Medical Center,
- 10 Division of Clinical Informatics, Department of Medicine, Boston, MA 02215, USA
- 11 +Corresponding author and
- 12 *Lead Contact:

- 13 Ramy Arnaout
- 14 Beth Israel Deaconess Medical Center
- 15 330 Brookline Avenue, DA709
- 16 Boston, MA 02215
- 17 rarnaout@bidmc.harvard.edu
- 18 617-538-5681

19 Abstract

<u>Background</u>. Regulatory approval of new over-the-counter tests for infectious agents such as
 SARS-CoV-2 has historically required that clinical trials include diverse groups of specific patient
 populations, making the approval process slow and expensive. Showing that populations do not
 differ in their viral loads—the key factor determining test performance—could expedite the
 evaluation of new tests.

<u>Methods.</u> 46,726 RT-qPCR-positive SARS-CoV-2 viral loads were annotated with patient
 demographics and health status. Real-world performance of two commercially available
 antigen tests was evaluated over a wide range of viral loads. An open-access web portal was
 created allowing comparisons of viral-load distributions across patient groups and application
 of antigen-test performance characteristics to patient distributions to predict antigen-test
 performance on these groups.

31 **Findings.** In several cases distributions were surprisingly similar where a difference was

32 expected (e.g. smokers vs. non-smokers); in other cases there was a difference that was the

33 opposite direction from expectations (e.g. higher in patients who identified as White vs. Black).

34 Sensitivity and specificity of antigen tests for detecting contagiousness were similar across most

35 groups. The portal is at https://arnaoutlab.org/coviral/.

<u>Conclusions.</u> In silico analyses of large-scale, real-world clinical data repositories can serve as a
 timely evidence-based proxy for dedicated trials of antigen tests for specific populations. Free
 availability of richly annotated data facilitates large-scale hypothesis generation and testing.

Funding. Funded by the Reagan-Udall Foundation for the FDA (RA and JEK) and via a Novel
 Therapeutics Delivery Grant from the Massachusetts Life Sciences Center (JEK).

41 Keywords: SARS-CoV-2, COVID-19, RT-qPCR, viral load, antigen test, precision medicine,

42 comorbidities, big data, real-world data

43 Introduction

44 Diagnosis of new infectious pathogens such as SARS-CoV-2 requires development of new 45 diagnostic tests, which must be evaluated and approved by regulatory agencies before they can be used for patient care. Such tests include over-the-counter (OTC) antigen tests, which have 46 47 been widely used for at-home testing in the context of COVID-19. In order to be approved, a new test must demonstrate a minimum level of clinical performance. Performance is typically 48 49 measured as the test's sensitivity, defined as the proportion of true-positive samples that have 50 a positive result, and its specificity, defined as the proportion of true negatives that have a 51 negative result. Clinical performance must be demonstrated in a defined patient population or 52 group and clinical context, for example inpatients as opposed to outpatients. However, at the 53 start of an outbreak, epidemic, or pandemic, there may not be enough information to know 54 whether a test can be expected to perform differently in some patient groups vs. others. 55 Therefore at the start of development, a new diagnostic test may be approved based on its 56 performance in the general population, not specific groups.

57 In contrast, as time goes on, evidence for clinical differences among specific groups may 58 emerge. As this happens, it becomes reasonable to ask whether a test might perform 59 differently in specific groups, with important implications for how and potentially even whether 60 that test should be used in a given clinical scenario. Ideally, this question would be answered by 61 conducting dedicated trials of the new diagnostic test in each group of interest. Unfortunately, 62 trials are expensive and slow. Also, the number of specific groups that may be of interest is large, since specific subgroups can be defined not only based on demographics (such as age, 63 race, and gender), comorbidities (such as diabetes, heart disease, or immunosuppression), and 64 65 care settings (inpatient vs. outpatient vs. emergency room) but also by the many possible combinations of each of these characteristics, which is an essential component of precision 66 medicine.¹ As a result, in practice it is prohibitively difficult to perform many separate trials on 67 68 specific groups for even a single diagnostic test, much less for the many tests that are likely to 69 be developed in response to a large-scale outbreak, such as has happened in response to the 70 COVID-19 pandemic. This is a problem for regulators, clinicians, and patients alike.

71 One solution is to apply a new test's various performance characteristics to real-world data 72 collected in the course of patient care. Such characteristics include results of existing trials as 73 well as analytical (i.e. pre-clinical) operating parameters such as the limit of detection (LOD). 74 The LOD is defined as the lowest concentration of virus that the test can detect in 95% of replicates. It is routinely determined by manufacturers and validated by clinical laboratories 75 before a test is put to use clinically.² The relationship between concentration and detection is 76 usually understood to follow an S-shaped curve;³ fitting it requires at least one additional 77 datapoint besides the LOD. The concentration of the virus may be measured as the viral load, 78 79 most often defined as the number of copies of viral mRNA per milliliter of testing material 80 (copies/mL).

81 "Real-world data" means the viral-load result of a reference diagnostic test that has already 82 been approved for the general population. Because this data is from the general population, it 83 will presumably include results on many specific patient groups. One can apply the 84 performance of the new test as described above to the set or "distribution" of viral loads from a 85 group to predict what proportion of patients in the group would have tested positive with the 86 new test. This proportion is the sensitivity of the new test for that group. In this way, one can 87 estimate clinical sensitivity without needing a dedicated trial on that group.

In this study, we apply this approach to COVID-19. We use the 46,726 positive SARS-CoV-2 RT-88 89 qPCR results our institution has performed as of this writing and use our electronic health 90 record to annotate each result according to the patient's demographics, comorbidities, and so 91 on. Importantly, we convert each PCR result from a Ct value to a viral load using robust (100% 92 code-coverage) and accurate publicly available software, as previously described.^{2,4–6} Although 93 PCR results are typically reported simply as positive or negative, qPCR is intrinsically 94 quantitative (the "q" in "qPCR"); we make use of this quantitative information in its natural unit 95 of measure (viral load). This is in contrast to Ct values, which are less useful because they vary 96 inversely with viral load and correspond to different viral loads on different PCR testing 97 platforms.

98 We focus especially on sensitivity and specificity for infectivity or contagiousness.

99 Contagiousness is of special interest given the public health focus on using quick, inexpensive 100 tests to curtail community transmission in a pandemic.^{7,8} Treating contagiousness as a function 101 of viral load, contagiousness can be estimated using a virus culture assay we previously 102 described in which a positive patient sample is applied to susceptible cells and monitored for virus replication. After an initial adsorption period, the cells are washed free of the initial virus 103 104 to eliminate carryover. The supernatant is then sampled on a timescale of days and tested by PCR for the presence of new virus.^{9,10} The lowest concentration of virus in a patient sample 105 106 from which new virus can be recovered is the contagiousness threshold. Because cells in culture 107 have no physical or distance barriers, no mucociliary elevator, and no protection via 108 medications or an immune system, we consider this threshold a conservative estimate. We 109 previously demonstrated this threshold is approximately 50,000 copies/mL and has been fairly stable even as the SARS-CoV-2 virus has evolved.9,10 110

111 Materials and Methods

Institutional review. Institutional Review Board approval was obtained for all described work
 under Beth Israel Lahey Health (BILH) IRBs 2022P000328 and 2022P000288. The Harvard T. H.
 Chan School of Public Health IRB20-1979 provided non-human subjects research determination
 for virus culture work.

116 **Defining specific patient groups.** We extracted the following information from our hospital's 117 clinical-research data repository: demographics (age, gender, and self-reported race/ethnicity), 118 socioeconomic status (using the median neighborhood household income for the patient's ZIP 119 code, obtained via the 2020 U.S. census, as a proxy), care setting (inpatient, outpatient, 120 emergency ward, or other institution), presentation/disposition (based on vital signs, which we 121 combined into a measure of initial presentation), outcome (survived, died with COVID-19 as the 122 cause of death, died with COVID-19 as an incidental finding), vaccination status (vaccinated, 123 unvaccinated, or unknown), treatment (CPT-encoded procedures, remdesivir (GS-5734; Gilead 124 Sciences, Foster City, CA) administration, steroid administration), comorbidities (according to

the Charlson Comorbidity Index:¹¹ body-mass index, diabetes, chronic heart disease, chronic 125 126 lung disease, chronic renal disease, liver disease, dementia, chronic neurological conditions, 127 connective-tissue disease, human immunodeficiency virus (HIV), and malignancy), and 128 immunosuppression status¹² (CD4+ T-count <100 cells/ μ L, hematologic malignancy, 129 chemo/immuno-modulating agent alone or in setting of solid malignancy, organ transplant, or rheumatologic/inflammatory condition). The rationale for extracting these data items 130 131 specifically was twofold: first, this list includes the complete COVID-19 core diagnostic data at 132 federal and state levels; second, it includes data necessary for calculating the well validated 4C 133 Mortality Score for SARS-CoV-2.¹³ ICD-10 codes corresponding to the listed comorbidities were determined by a physician (Dr. Arnaout) following prior methodologies¹⁴ but updated for 2022-134 135 2023.

At presentation, patients were considered sick if any of the following were true within 1 day of the PCR test sample: systolic blood pressure <90 mmHg, diastolic blood pressure <60 mmHg, heart rate >100 beats per minute, respiratory rate >18 breaths per minute, or temperature >99.1°F. They were otherwise considered well, with the exception that if no values were recorded (NULL in the data repository) for all criteria, presentation was considered unknown and therefore not assigned.

142 Patients were designated as immunocompromised at the time of PCR testing if one of the 143 following were true: on their most recent T-cell subset analysis report, their absolute CD4+ cell 144 count was <100 cells/µl; they had a diagnosis of either lymphoma or leukemia associated with a 145 healthcare encounter (visit, admission, or phone call) either before the PCR test or within 60 146 days after the PCR test; they were on any of the following medications on an ongoing basis, 147 prescribed prior to the PCR test and with enough refills to include the time up to 30 days prior 148 to the PCR test: abatacept, adalimumab, anakinra, azathioprine, basiliximab, budesonide, 149 certolizumab, cyclosporine, daclizumab, dexamethasone, everolimus, etanercept, golimumab, 150 infliximab, ixekizumab, leflunomide, lenalidomide, methotrexate, mycophenolate, natalizumab, 151 pomalidomide, prednisone, rituximab, secukinumab, serolimus, tacrolimus, tocilizumab,

152 tofacitinib, ustekinumab, or vedolizumab. Otherwise, they were designated not

immunocompromised.

154 Supplementary Table 1 provides further details for the above methods.

<u>Viral load</u>. The SARS-CoV-2 RT-qPCR testing in this study was performed on three Abbott
 Molecular platforms: m2000, Alinity m, and Alinity 4-Plex (Abbott Molecular, Des Plaines, IL,
 U.S.A.). These detect identical SARS-CoV-2 N and RdRp gene targets. They are extremely
 sensitive, with LOD of ~100 copies/mL. They output a quantitative fractional cycle number
 (FCN), a type of Ct value described in detail elsewhere.¹⁵ Together these platforms accounted
 for 46,726 positive tests.

161 Ct values were converted to viral loads in units of copies of viral mRNA per mL using the public 162 Python package *ct2vl* as previously reported.⁴ Briefly, this software was validated via calibration 163 curves established for all platforms using an extended SeraCare panel (LGC Seracare, Milford, 164 MA) panel based on a SARS-CoV-2 genome incorporated into replication-incompetent, 165 enveloped Sindbis virus and calibrated based on digital PCR at US National Institutes of Standards and Technology (NIST) and LGC/Seracare.¹⁶ Validation material ranged in viral load 166 167 from 300 to 10⁶ viral genome copies/mL. Results were harmonized with the cycle threshold for 168 a spiked internal control also amplified in each SARS-CoV-2 assay to confirm lack of PCR 169 inhibition and accurate viral load output. The standards, modeling SARS-CoV-2 virus, were run 170 through all stages of sample preparation and extraction to allow appropriate comparison with identically processed patient samples. R^2 was ~0.99 for all calibration determinations, indicating 171 172 assays are robustly quantitative.

Presumed SARS CoV-2 variant. Presumed variant was inferred from the date of sample
 collection based on the data presented by Covariants (https://covariants.org) showing the
 frequency of sequencing particular variants in Massachusetts, the United States, and other
 locations.¹⁷ Specimens from before June 7, 2021 were annotated as being an early variant.
 Specimens from between July 7, 2021 and December 6, 2021 were annotated delta variant.

Specimens from after January 3, 2022 were annotated as omicron variant. Results from the
month between windows, when more than one major variant was common, were not
annotated with a presumed variant and are omitted from by-variant comparisons.

181 Evaluation of antigen tests vs. PCR. Patients seeking COVID testing at a drive-through testing site near Boston affiliated with our medical center^{5,6} between May 23 and November 4 of 2022 182 183 were offered the opportunity to participate in a separate arm, providing a comparative, parallel 184 prospective study. This represented community testing for both symptomatic and 185 asymptomatic individuals with diverse demographics (age, race, sex, socio-economic status). 186 Each patient who consented had both a standard-of-care PCR test and two OTC antigen tests 187 performed (Abbott BinaxNow COVID-19 Ag Card and CareStart COVID-19 Antigen Home Test). 188 The PCR test was performed on material collected with a nasopharyngeal swab. SARS-CoV-2 RT-189 qPCR testing was performed using the Abbott m2000 RealTime or Alinity m SARS-CoV-2 assays 190 according to the manufacturer's instructions, yielding, for each positive sample, a Ct value 191 which was converted to viral load as previously described. Specimens for the antigen tests were 192 collected with separate nasal swabs for each test, according to the manufacturer's instructions. 193 These were collected and the tests performed by study personnel after informed consent was 194 obtained on-site within the time-frame constraints detailed in each test's instructions for use, 195 as per IRB. In order to extrapolate antigen-test performance from this subset to all patients, 196 positivity vs. viral load was modeled by logistic regression (the LogisticRegression function in Python's scikit-learn library).¹⁸ LogisticRegression converges on optimal parameters in a model 197 198 predicting the probability of a positive test based on viral load. Parameters were predicted 199 separately for each test. The equation for probability was a standard sigmoid constrained to the 200 range 0-1 (i.e., the lowest probability is zero and the highest probability is 1): p(test success) = $\frac{1}{1+e^{-k(v-v_0)}}$ where v, the independent variable, is log₁₀ of the viral load. This constraint leaves 201 202 two free parameters: v_0 is the midpoint, i.e. the model's estimate of where the success rate 203 passes 50%, while k controls the steepness, i.e. the change in viral load to change in probability 204 of being positive.

205 **Contagiousness.** Samples were then stored at 4°C until contagiousness testing. This was done 206 within a four-day time period. We previously validated that freeze-thaw does not impact viral 207 viability and will bank remaining samples for future investigations. Quantitative viral culture 208 was performed on a random sample of PCR-positive samples. Vero E6 cells (ATCC CRL-1586) 209 were seeded on a 6-well flat bottom plate at 0.3×10⁶ cells per well in Eagle's minimum essential 210 media (EMEM) containing 1% antibiotic-antimycotic, 1% HEPES and 5% fetal calf serum (FCS, 211 Gibco) grown to confluence at approximately 1×10^6 cells per well, inoculated with 250µL of patient sample, and incubated at 37°C for 24 hours for viral adsorption, as previously 212 213 described.^{10,19–21} Carryover of non-viable viral RNA present in samples was limited by washing 214 cell cultures after the 24-hour viral adsorption and adding fresh EMEM composite media with 215 reduced FCS to 2% for viral growth, meaning detectable virus represents viable replicating virus. 216 On days 3 and 6, cell culture supernatant was removed and added to 800µL of VXL buffer 217 (QIAGEN, German, MD) (1:1 ratio) for subsequent nucleic acid extraction and detection of virus 218 by PCR. Viral load in culture supernatants on days 3 and 6 served as a quantitative surrogate for 219 viable (i.e. replication-competent) virus in the patient sample and provided a measure of the 220 magnitude of sample infectivity. SARS-CoV-2 RT-qPCR testing of Vero cell culture supernatants 221 was performed using the Abbott m2000 Real-Time or Alinity m SARS-CoV-2 assays according to 222 the manufacturer's instructions. The contagiousness threshold was determined by the 223 threshold patient-sample viral load value resulting in detectable culture viral load.

224 Whole-genome viral NGS. Next-generation-sequencing (NGS)-based sequencing of select PCR-225 positive samples from the viral antigen evaluation study was performed as follows. Full-length 226 SARS-CoV-2 viral genome sequencing was performed on the Oxford Nanopore MinION system 227 (≥R9.4 flowcell; Oxford Nanopore Technologies-ONT, Oxford, UK) using the guppy basecaller and the downstream ARTIC network bioinformatics pipeline for genome assembly.^{22,23} The 228 229 workflow was run on a 2021 Intel Core i9-11900 Rocket Lake 3.5GHz 8-core LGA 1200 boxed 230 processor with NVIDIA A5000 GPU. Standard coverage and guality metrics and plots were 231 produced, single-nucleotide variants were recorded, and variants assigned using NextClade.²⁴

232 Web portal and privacy protection. The portal was written using Svelte and d3 for the 233 interactive frontend and Python run against a Postgres database for the backend. To reduce re-234 identification risk, ages were jittered by adjusting the patient's date of birth by a random 235 number of days (drawn from a Gaussian distribution with a standard deviation of two years) 236 before calculating patient's age at the time of each test. Groups smaller than 4-8 patients are 237 suppressed and therefore not viewable. Revealing exact sizes of such small groups defined by 238 multiple patient characteristics would pose a re-identification risk. To prevent inferring the sizes 239 of these groups by subtraction of viewable group sizes, viewable group sizes are jittered by 240 dropping approximately 0.5-1% of the data on any split by patient feature. To maximize 241 consistency of the results of jittering as data are updated, jittering was performed using 242 random number seeds based on pseudo-identifiers (which are never uploaded and thus 243 inaccessible to/safe from the web client). For ease of visualization, plots of viral load 244 distributions are shown as kernel-density estimates (i.e. smoothed) using a Gaussian kernel of 245 width 0.25 log10 viral load units (~1.7-fold).

246 Statistical tests. The geometric mean viral load for each patient group was calculated as a 247 summary statistic. The geometric (as opposed to arithmetic) mean was chosen because viral loads vary over many orders of magnitude.² The Kolmogorov-Smirnov test (KS; 248 249 scipy.stats.kstest) was used to compare distributions. This test was used because data were not 250 distributed normally and KS does not require normality (unlike, for example, the t-test, which 251 requires normal distributions). KS tests the null hypothesis that the distributions of viral loads for two patient groups are statistically indistinguishable.²⁵ The p-value gives the probability that 252 253 distributions from the two groups are drawn from the same underlying distribution. A large p-254 value means the two groups are statistically indistinguishable; a small p-value means they are 255 different. Interpretation of p-values as significant vs. not significant requires a significance 256 threshold, which requires correction for multiple comparisons if multiple comparisons are 257 performed.^{26,27} Because the number of comparisons performed via the web portal is up to the 258 user, un-corrected p-values are reported, with interpretation as significant or not significant left 259 to the user.

260 Software and hardware. Data extraction, annotation, statistics, and analyses were performed

using standard Unix tools and Python 3.9+ using the pandas, numpy, scipy, and scikit libraries

and the interactive Jupyter notebook environment. Figures were created using Python graphics

libraries matplotlib and seaborn, and OmniGraffle 7 (The Omni Group, Seattle, WA).

264 **Results**

265 <u>A web portal for large-scale real-world SARS-CoV-2 viral load results for different patient</u>

266 groups. 46,726 COVID-19 PCR results representing approximately 39,180 unique individuals 267 were converted to viral loads and annotated for patient demographics, comorbidities, 268 presentation, treatment, and socioeconomic status and made available for interactive 269 investigation via a public web portal at https://arnaoutlab.org/coviral/ (Table 1). The portal^{28,29} 270 allows users to visualize the viral load distribution for any patient group, to compare 271 distributions between groups, and to estimate, for each group, the sensitivity and specificity of 272 a given OTC test for detecting contagious individuals. Users can define and compare complex 273 subgroups by selecting multiple characteristics via checkboxes in the user interface (Fig. 1). In 274 this work, all the figures that contain distributions are direct screenshots from the portal.

275 **Overall viral load distributions.** Viral loads varied over nearly 10 orders of magnitude, from 7 276 copies/mL (the lowest our system will report) to 1.5 billion copies/mL (99th percentile). This 277 extraordinary range is consistent with observations from early in the pandemic (spring-summer 278 of 2020).² The referenced early observations suggested that viral loads were, to a good 279 approximation, distributed fairly uniformly over the range. In contrast, the current dataset, 280 which is ten times as large (46,726 results vs. 4,774 in the previous work²), demonstrates clear 281 bimodality: patients' viral loads tend to be either very low, with a peak around the LOD of 100 282 copies/mL, or else very high, with a peak around 100 million copies/mL (Fig. 2). This bimodality 283 is apparent in retrospect (e.g., Fig. 2a of Arnaout et al. 2021²) but required a large dataset to 284 visualize clearly. Further research is needed to understand the reason(s) for these two peaks.

285 Viral load comparisons among patient groups: remdesivir treatment and patient

286 presentation. The web portal allows statistical comparisons of many thousands of specific 287 patient groups. Here we describe several examples that are illustrative of the questions that 288 can be asked and answered using this resource. Remdesivir (Gilead Sciences, Foster City, CA) is 289 an intravenously administered RNA polymerase inhibitor initially approved by the FDA for treatment of SARS-CoV-2 in hospitalized adults and adolescents.³⁰ Of the 46,726 test results in 290 291 our dataset, 688 were from patients who then received remdesivir treatment. In practice, at 292 our institution, remdesivir was used for sicker patients. We hypothesized that viral loads would 293 be higher on average in patients who received remdesivir and in sicker patients. The data 294 supported this hypothesis: viral loads were higher on average in both remdesivir-receiving and sicker-appearing patients, with means of 8.6x10⁵ copies/mL in patients who received remdesivir 295 296 vs. 1.2x10⁵ in those who did not (Fig. 3a) and 9.4x10⁴ in sick-appearing patients vs. 4.1x10⁴ in 297 well-appearing patients (Fig. 3b). In both cases, the difference was due to a greater fraction 298 patients in the high-viral-load peak. This was especially clear in the remdesivir comparison (Fig. 299 3a). In each case, the KS p-value was 4.3×10^{-16} , which we interpret as rejecting the null 300 hypothesis of no difference, with high confidence. These are examples in which the data 301 confirmed hypotheses regarding differences in viral load.

302 Unexpected findings: pulmonary disease. Serious cases of COVID-19 are marked by life-303 threatening respiratory distress. This evolution became less common with the emergence of 304 the omicron strain and the increasing prevalence of prior immunological exposure including 305 vaccination. We hypothesized that patients with pulmonary disease would have higher viral 306 loads than patients without pulmonary disease, especially for early viral variants, which had a 307 stronger tropism for lung as opposed to the upper respiratory tract. However, this hypothesis 308 was not supported (Fig. 3c). Viral loads for the 975 patients with pulmonary disease tested 309 during the early-variant era were statistically indistinguishable from those for the 27,308 310 patients with no pulmonary disease who were tested during the same time period. This is an 311 example of unexpected findings that this dataset and its web-portal interface can reveal.

312 **Comparisons among multiple groups: survivorship and causes of death.** The web portal also 313 allows users to compare more than two groups of patients at a time. In quantifying mortality 314 during the pandemic, one distinction of value has been between individuals who died with 315 COVID-19 as the proximal cause of death and individuals who died with COVID-19 as an 316 incidental finding. We compared these two groups with survivors (Fig. 3d). We found that the 317 398 patients who died from COVID-19 in our dataset had higher viral loads than either of the 318 other two groups, and that viral loads were statistically indistinguishable between the 319 approximately 46,000 survivors and the 143 patients who died with COVID-19 as an incidental 320 finding (p=0.07). For ease of comparison, the web portal displays distributions in a ridgeline plot 321 from lowest to highest mean, top to bottom. When there are three or more groups, p-values 322 are displayed as a heatmap, accompanied by explanatory text. (Because KS p-values are

323 symmetric, only the top half of the heatmap is shown.)

324 **Complex patient subgroups: race and presumed variant.** The ability to interrogate complex 325 subgroups by checking multiple boxes in the web-portal interface allows more subtle 326 investigations. For example, Black patients have experienced disproportionate morbidity and 327 mortality during the pandemic.³¹ However, the 13,806 patients who self-reported as White in 328 our dataset on average had slightly higher viral loads than the 8,299 who self-reported as Black (KS $p=3.3\times10^{-13}$). That the viral loads in the White group were on average higher suggests that 329 330 differences in outcome between these groups are not explained by differences in viral load (Fig. 331 3f-g), despite the clear relationship between viral load and survivorship described above (Fig. 332 3d). Interestingly, the observed difference is more pronounced during the delta-variant wave 333 (Fig. 3h). During the delta wave (July 7, 2021 to December 6, 2021), viral loads were on average 334 three times as high for White patients (8.0×10^5 copies/mL, n=1,024) as Black patients (2.7×10^5 copies/mL, n=665; KS test $p=5.2 \times 10^{-8}$) with a distinctly sharper high-viral-load peak in White 335 336 patients. This difference was greater in patients over 30 years old and was almost entirely 337 absent in patients under 30 (30-60 y.o.: 398 Black patients and 719 White patients, $p = 2.5 \times 10^{-5}$; 338 <30 y.o.: 266 Black vs. 299 White patients, p=0.14). In contrast, viral load distributions for Black and White patients were more similar for both early in the pandemic and during the omicron 339 variant time period (p=4.0x10⁻⁵ for 4,393 Black and 7,042 White patients and p=0.02 for 2,295 340

Black and 4,341 White patients, respectively). This example illustrates the utility and (statistical)
power of the portal for investigating subgroups of interest.

343 Antigen test performance. In the head-to-head comparison of PCR and antigen test results, 281 patients consented to participate. Of the PCR samples collected, 277 were tested; the 344 345 remaining four were mishandled or leaked. Of the 277, 65 had a positive COVID-19 result by 346 PCR (23%). The PCR-positive samples were all tested on either the Alinity m SARS-CoV-2 real 347 time RT-PCR assay or the Alinity m Resp-4-Plex PCR assay. Viral loads in the PCR-positive patients ranged from approximately 10 to approximately 10⁹ copies/mL, with a peak in the 348 distribution between 10⁶ and 10⁸. Of the 65 positive samples, 3 were sequenced and 20 349 350 selected at random were used to assess contagiousness in viral culture.

351 Antigen test performance. Of the 65 patients with positive PCR tests, 43 tested positive on the 352 Binax antigen test and 40 tested positive on the CareStart antigen test. No invalid antigen tests 353 (lacking the control line) were observed. Only one of the patients who tested negative by PCR 354 tested positive on the antigen tests (both Binax and CareStart), confirming the high specificity 355 of these tests. The proportion of positive antigen tests varied with viral load. At viral loads less 356 than 10³ copies/mL, both antigen tests were always negative; at viral loads greater than 10⁷ 357 copies/mL, both antigen tests were always positive. However, there was an overlap of antigen-358 test-positive and antigen-test-negative results at intermediate viral loads (Fig. 4a). k and v_0 359 values (see Methods) were comparable between the two antigen tests (k=1.184, v_0 =4.538 for 360 Binax and k=1.142, $v_0=4.995$ for CareStart). The resulting S-shaped curves were used to predict 361 antigen test performance in the web portal.

The OTC antigen tests that have been widely available on the market since 2021 are
 considerably less sensitive than RT-qPCR for detecting SARS-CoV-2 infection. However, because
 their LODs are generally above the contagiousness threshold, they are quite sensitive for
 detecting contagiousness.¹⁰ Based on our clinical experience, we hypothesized that antigen
 tests would perform similarly on different patient groups and subgroups; this hypothesis was
 largely supported (Fig. 4b-d). The web portal also allows users to estimate sensitivity and

368 specificity for the BinaxNow COVID-19 Ag Card and CareStart COVID-19 Antigen Home Test,

369 based on the modelled performance curves, on any sufficiently large user-selected patient

group (Fig 6). The two tests performed well: sensitivities for detecting contagiousness were

371 roughly 0.85-0.90 across patient groups.

372 Contagiousness for omicron-era virus. For early-pandemic and delta-wave strains of SARS-CoV-373 2, the threshold viral load for contagiousness has previously been found to be approximately 374 10⁵ copies/mL.¹⁰ For omicron variants, we found that the threshold is statistically 375 indistinguishable from this, at 4.5x10⁴ copies/mL (confidence interval, 1.1x10⁴-1.9x10⁵ 376 copies/mL; p=0.23, Fig. 5). The omicron threshold was based on 20 PCR-positive results from 377 our head-to-head clinical trial of 277 total patients. We confirmed that the dominant strain 378 circulating in the Massachusetts Bay area was omicron (BA5.2/Clade 22B) via next-generation 379 sequencing, with only rare single-nucleotide differences relative to those already described (Fig. 380 6a-d). Because the strain mix in Massachusetts (Fig. 6e) has been highly representative of the 381 strain mix in the country as a whole throughout the pandemic (Fig. 6f), these results support 382 the generalizability of these findings from a particular geographic area to the entire population.

383 Discussion

384 The COVID-19 pandemic has proven a catalyst for accelerating medical advances, including the 385 development of more efficient methods for developing and testing critical diagnostic assays.^{32–} 386 ³⁷ It has also drawn attention to the value of reliable public data, including large public 387 datasets.^{38–42} Here we describe such a dataset, to our knowledge the first large dataset of SARS-388 CoV-2 viral loads in patients across the history of the pandemic through to the present day. The 389 rich clinical annotations of this dataset reveal similarities and differences in viral loads among 390 patients by demographics, presentation, and comorbidity as well as by vaccination status, 391 treatment, and socioeconomic status. Protected patient data was safeguarded by multiple 392 mechanisms. The data revealed cases in which differences were expected as well as cases in 393 which they were unexpected. The size of the dataset and extent of the annotation allow more 394 comparisons than can reasonably be summarized in a single publication; availability of this

dataset via the web allows anyone—clinicians, investigators, developers, regulators, and
patients, alone or with the assistance of artificial intelligence and/or machine learning (AI/ML)based tools—to explore and conduct research, to test existing hypotheses, and to generate
new research questions.

399 The clinical utility of measuring and investigating viral load in SARS-CoV-2 has been 400 demonstrated.^{43–46} This is consistent with both the advantage of viral loads relative to Ct 401 values^{47,48} and their utility in earlier viral infections such as HIV and hepatitis C (HCV). SARS-402 CoV-2 viral loads have already proven useful in the development and characterization of COVID-403 19 diagnostics in multiple contexts, including testing on nasopharyngeal secretions, nasal secretions, and saliva.^{5,6} Here we demonstrate their potential to regulators as a tool to 404 405 streamline evaluation of new OTC tests. Specifically, we demonstrate that a test's analytical 406 performance measure, namely the LOD, can be used to estimate that test's clinical sensitivity 407 for detecting contagiousness in any patient group, without having to conduct a dedicated 408 clinical trial for that group. The alternative of innumerable dedicated trials is beyond reasonable 409 expectations of the financial capability of developers or the bandwidth of their clinical testing 410 partners. For this reason regulatory agencies such as the FDA have expressed interest in 411 methods that use large-scale real-world data to streamline test evaluation.

412 Two assumptions implicit in this approach are worth mention. First, we model the success rate 413 of antigen tests solely as a function of viral load. The assumption is that no other non-negligible 414 factor varies systematically between patient groups. Second, we assume that the curve-415 success rate as a function of viral load—can be adequately predicted from the data from a fairly 416 small study. There are two possible sources of error in this curve: sampling error, which can be 417 reduced by increasing the number of subjects sampled; and lack-of-fit error, the error inherent 418 in trying to fit a function of the wrong form. The function used in the web portal's calculations, 419 was chosen on the basis of its history of use in dose-response-type situations, but carries the 420 (reasonable) assumptions that the probability increases smoothly and continuously with 421 increasing viral load, and approaches 0 with sufficiently low viral load and 1 with sufficiently 422 high viral load. These constraints leave only two free parameters, which is desirable for

statistical power and robustness to the noise inherent in any such study (e.g., sampling errorand measurement error).

425 A user of the web portal who is accustomed to thinking of test quality solely in terms of LOD 426 (limit of detection) might initially be surprised that the portal prefers two parameters, not one, 427 to define an antigen test's performance. In effect, the LOD parameter sets the location of the S-428 shaped curve that relates viral load and performance, and the second parameter—here, the 429 50% detection threshold—sets the S-shaped curve's steepness. Without the second parameter, 430 one could fit a curve in which the sensitivity is 0% at all viral loads below the LoD, and 95% at 431 any higher viral load, which is clearly quite different from the relationship observed in the head-432 to-head study. How different the true shape of the antigen test performance curve is from the 433 logit function used here, and thus whether fitting a different function would work better, can 434 be elucidated by larger head-to-head studies; however, in the midst of a public health 435 emergency, the cost in time of sampling more subjects must be weighed against the value of 436 complete certainty. At any rate, the fitting error was low.

437 Three important limitations to the dataset in its current form also deserve mention. The first is 438 due to incompleteness of some of the data fields, for example presentation and vaccination 439 status (Table 1). Presentation information was only sometimes available in structured form in 440 our data repository; we did not attempt to extract data from notes to complement incomplete 441 records. Vaccination status was likewise only sometimes available in a structured manner; 442 integration with state-level records could potentially fill in missing records. Second, patient-443 level annotations are not yet available for download as part of the dataset. Making viral loads 444 freely and easily available for patient groups required significant attention to avoid potential 445 loopholes that might risk patient privacy via identifiability. Methods included suppressing data 446 transmission for groups that were small enough to present potential "journalist risk,"⁴⁹ jittering 447 counts to prevent deduction of the sizes of suppressed groups, and rounding viral loads to two 448 log-scale decimal places.⁵⁰ Further work is necessary to make patient-level annotations 449 available. Third and finally, the size of the dataset, while large, is still insufficient for the 450 smallest groups—for example, cystic fibrosis patients, patients who recently delivered, or

Native Americans—to be sufficiently sizeable to draw robust conclusions. One solution is to add
data from other care-giving institutions that performed substantial COVID-19 testing; another is
to supplement existing large datasets, for example the 50-million-person CVD-COVID-UK
initiative, with viral loads. The free availability of methods to convert from Ct values to viral
loads facilitates such advances.⁴

456 As part of the drive toward precision medicine, clinical care benefits from personalization of 457 diagnostic testing: the right test for the right patient, where the importance of patient 458 heterogeneity is increasingly accepted. We have demonstrated that large-scale real-world data 459 can assist this effort by enabling the estimation of personalized clinical sensitivities and 460 specificities without the need for dedicated clinical trials on every patient group. This work is 461 generalizable beyond COVID-19. Laboratory testing is an exceptionally rich source of real-world 462 medical information. It is the highest volume medical activity, with some 20 billion tests 463 performed each year in the United States alone. It is also the most cost-effective, costing just 464 pennies on the healthcare dollar. It is integral to decision-making across medicine, for patients 465 at every level of acuity, from screening to emergencies. Its results are almost always numerical 466 or categorical, making it especially amenable to modern approaches like machine learning. And 467 computational re-analysis is substantially less expensive than de novo trials. The present work 468 supports the view that meaningful value can come economically from additional repurposing of 469 the vast stores of real-world laboratory results that exist in healthcare institutions.

470 Acknowledgements

The authors acknowledge Elliot Hill for assistance on plugging ct2vl into the data processing
workflow; to Timothy Graham, Gail Piatkowski, Baevin Feeser, and Griffin Weber for their
advice and guidance on extracting data from EMR databases; to funding from the Reagan-Udall
Foundation for the FDA (R.A.); and to funding via a Novel Therapeutics Delivery Grant from the
Massachusetts Life Sciences Center (J.E.K.). We would also like to acknowledge Abbott
(Scarborough, ME) for provision of the Binax Now antigen tests and Ginkgo Bioworks (Boston,
MA) for provision of CareStart antigen tests used in this study.

478 Author Contributions

- 479 Conceptualization, J.K. and R.A.; Software, A.M.; Investigation, D.H., E.C., S.D., and M.Y.;
- 480 Resources: S.R.; Data Curation, A.M.; Writing Original Draft, R.A. and A.M.; Writing Review
- 481 & Editing, P.K. and J.K.; Visualization, T.S., D.B., A.M., and R.A.; Supervision, R.A; Funding
- 482 Acquisition, P.K., S.R., and R.A.

483 **Declaration of interests**

484 The authors declare no competing interests.

485 Table and Figure Legends

- 486 **<u>Table 1: Summary of patient characteristics</u>.** Shown are counts for select high-level categories
- 487 as of April 14, 2023. Counts may differ somewhat from the counts presented through the web
- 488 portal as a result of jittering and as more data continues to be added through the portal. Note
- that counts broken down by characteristics do not add up to the total, because of the nulling
- 490 out of some data to reduce re-identification risk (see Methods).

491 Table S1: Detailed criteria for defining patient characteristics, Related to Methods. Criteria for

- 492 each of the characteristics available on the portal are described.
- 493 Fig. 1: Patient characteristics available for defining patient groups and subgroups. This
 494 screenshot from the web portal demonstrates the ability for users to define patient groups by
 495 demographic, comorbidity, treatment, vaccination status, pandemic era, and so on, using
 496 checkboxes.
- 497 Fig. 2: Overall bimodal distribution of viral loads. When no checkboxes are selected to
 498 constrain or partition the dataset, users see the distribution of all viral loads. The marked
 499 bimodal distribution is clearly apparent.

500 Fig. 3: Viral load comparisons by remdesivir treatment, patient presentation, and outcome.

501 Screenshot from the web portal. Viral loads are higher in (a) patients who received remdesivir 502 vs. patients who did not receive remdesivir and in (b) patients who presented as ill-appearing 503 vs. patients who presented as well-appearing (see Table S1 for precise definitions). Note the 504 bimodal distributions, with a low-viral-load peak and a high-viral-load peak. (c) Viral load 505 distributions and pairwise p-values by presence or absence of pulmonary disease for patients 506 during the early variant era. (d) Patients who died from COVID-19 had higher viral loads than 507 either patients who died with COVID-19 as an incidental finding or survivors. Viral loads for 508 were statistically indistinguishable between the latter two groups. The web portal displays 509 distributions in a ridgeline plot from lowest to highest mean, top to bottom. (e) Because there 510 are three or more groups, p-values are displayed as a heatmap, accompanied by explanatory 511 text. Because KS p-values are symmetric, only the top half of the heatmap is shown. Fig. 3f-h: 512 viral load distributions by self-reported race and by race-plus-presumed variant. (f) Viral load 513 distributions by race. (g) Statistical comparisons among these distributions. (h) Viral load 514 distributions between Black vs. White patients in the delta-variant era.

515 Fig. 4: Antigen test results from head-to-head trial and performance on patient subgroups. (a)

516 Each antigen test result for each PCR-positive patient, vs. log₁₀ of viral load according to the 517 simultaneous PCR test. (b) Antigen test performance on patients in neighborhoods stratified by 518 median household income. (c) Performance of BinaxNow COVID-19 Ag Card on patients with 519 median household income >\$130,000. (d) Performance of BinaxNow COVID-19 Ag Card on 520 patients with median household income <\$52,000. The user can use the radio buttons to select 521 any of the patient groups in the viral load distributions in the top section of the web portal. The 522 imputed positive antigen-test results will appear as a lighter shade, and the negative results a 523 darker shade.

524 Fig. 5: Determination of the contagiousness threshold for omicron-era SARS-CoV-2 strains.

525 Below a certain viral load in the patient sample (x-axis), no virus was recoverable from culture

526 (y-axis, maximum of day 3 and day 6 supernatants). For viewing convenience, culture-negative

527 samples are plotted at 0.1 copies/mL (dotted line, 1 copy/mL). The gray region shows the

528 confidence interval for the threshold. The red line shows the midpoint of this region (on the
529 log10 scale), 45,000 copies/mL, as the most likely threshold.

530 Fig. 6. Sequencing late-2022 strain and generalizability of Massachusetts-level results to the

- 531 **United States as a whole.** Results of sequencing of a BA5.2/Clade 22B patient sample from
- 532 Aug.-Sep. 2022 (97.6% coverage). (a) Sample relative to COVID-19 phylogeny (with clade labels).
- 533 (b) First 64 of the 72 nucleotide substitutions relative to the original Wuhan strain. (c) 52 amino
- acid substitutions relative to the Wuhan strain. (d) The five unique ("private") mutations
- relative to the phylogenetic tree. (e) Distribution of strains in Massachusetts near the time of
- the sample according to covariants.org. (f) Comparison by frequency of the strains circulating in
- 537 Massachusetts to those circulating in the United States at the same times demonstrating
- 538 generalizability of Massachusetts-state variant patterns to the country as a whole. Red line, 1:1.
- 539 Gray, early strains; purple, delta strains; green, omicron strains. R² is for least-squares linear
- 540 regression of USA vs. Massachusetts data (regression slope=0.97, intercept=0.00).

541 Tables and Figures

542	Table 1: Summary of patient characteristics		
543	Sex		
	Female	25,884	
	Male	20,608	
544	Age		
	<30 years old	12,446	
545	30-60 years old	21,889	
	> 60 years old	12,100	
F.4.C	Self-reported Race or Ethnicity		
540	Unknown/Other	14,530	
	White	13,806	
547	Black	8,299	
	Hispanic	7,540	
F 4 0	Asian/Pacific Islander	2,472	
548	Setting		
	Inpatient	2,157	
549	Outpatient	11,758	
	Emergency room	1,779	
550	Other institutions	31,031	
550	Variant		
	Early	28,289	
551	Delta	2,911	
	Omicron	11,264	
FF2	Vaccination status		
552	Vaccinated	6,806	
	Unvaccinated	6,960	
553	Unknown	32,732	
	Outcome		
FF 4	Died from COVID-19	398	
554	Died with COVID-19 as an incidental finding	143	
	Survived	45,938	
555	Testing platform	24.242	
		24,243	
		20,593	
556	Abbott Alinity 4-plex	1,889	
	Iotal	46 726	
55/		40,720	

Table S1: Detailed criteria for defining patient characteristics, Related to Methods

Table 1	
Checkbox name	Notes
Acquired immunodeficiency	ICT10_codec+ [#010# #000711# #000712# #000710# #00071# #00071# #00071# #214#]
syndrome	ICUTO COLOS. [520 , 030/11 , 030/12 , 030/13 , 030/13 , 030/2 , 030/3 , 221]
Age	years
Blood products	CPT4 codes: ["P9012","P9016","P9047","P9059","P9073"]
0141	kilograms/(meter**2); allowed values: {"Underweight": "bmi < 18.5 AND age > 17", "Healthy weight": "bmi >= 18.5 AND bmi < 25 AND age > 17", "Overweight": "bmi >= 25 AND bmi < 30 AND age > 17", "Obese": "bmi
BIVII	>= 30 AND age > 17"}
Acquireo immunodericiency syndrome Age Blood products BMI	I CD10 codes: ["620","098711","098712","098713","098719","09872","09873","221"] years CPT4 codes: ["P9012","P9016","P9047","P9059","P9073"] kilograms(inceter*2); allowed values: ["Underweight": "bmi < 18.5 AND age > 17", "Healthy weight": "bmi >= 18.5 AND bmi < 25 AND age > 17", "Overweight": "bmi >= 25 AND bmi < 30 AND age > 17", "Obes >= 30 AND age > 17"]

Cancer	 India de La (1980). Orazi, Costa, Cost
Cerebrovascular disease	ICD10 codes: [G450', G451', G452', G453', G453', G454', G458', G469', G460', G461', G462', G463', G464', G465', G466', G467', G468', H3400', H3401', H3402', H3403', H3410', H3411', H3412', H3412', H3412', H3412', H3412', H3412', H3412', H3421', H3422', H3423', H3423', H3423', H6001', H6001', H6001', H6001', H6001', H6002', H6002', H6002', H6002', H6003', H6031', H6032', H6031', H6032', H6031', H6032', H6031', H6032', H6031', H6032', H603', H605', H607', H608', H609', H611', H612', H613', H614', H615', H6131', H61
Connective tissue disease	ICD10 codes: ["M05', "M06', "M315', 'M32', 'M33', 'M34', 'M353', 'M360']
Presentation	Sick-appearing (any of systolic blood pressure <90 mmHg, diastoloc blood pressure <60 mmHg, heart rate >100 beats per minute, respiratory rate >18 breaths per minute, or temperature >99.1°F within 1 day of PCR test samble / ss. we have a single / ss. w
Vaccination status	Vaccinated vs. unvaccinated vs. unknown
Vaccination status Dexamethasone	Aminger Va. New appearing. Vacinated Va. Unix constant. Machined Va. Sciences matches to case-insensitive searches for the string "dexamethasone" ICD10 codes:[E08007, E08017, E08117, E08217, E08227, E08297, E083117, E083127, E083217, E0832137, E0832197, E083297, E0832917, E083297, E083397, E08337, E083397, E093317, E0933117, E093317, E093327, E093327, E0933297, E093337, E09

558

Diabetes

E 10049, E 10049, E 10049, E 10049, E 10049, E 100400, E 100400, E 100400, E 100400, E 100400, E 100400, E 10049, E 1004

E103399, 'E103399, 'E10341', 'E10341', 'E103419, 'E10349', 'E10352', 'E10351', 'E10351', 'E10351', 'E10352', 'E10353', 'E10359', 'E11359', 'E11379', 'E11317', 'E11

Table S1, continued

Table 1, Continued	
Checkbox name	Notes (G041, G800, G801, G802, G808, G809, G800, G810, G810, G8101, G8102, G8104, G8104, G8110, G8111, G8112, G8113, G8114, G8190, G8191, G8192, G8193, G8194, G8220, G8221, G8222, G8221, G8222, G8221, G8222, G8222, G8221, G8222, G8232, G8234, G9253, G9054, G9052, G9062, G9022, G9022, G9022, G9024, G9022, G9024, G9022, G9024, G9022, G9024, G9022, G9024, G9022, G9032, G9032, G9034, G9032, G9044, G9042, G9022, G9022, G9032, G9033, G9034, G9032, G9033, G9034, G9032, G9034, G9032, G9033, G9034, G9032, G9034, G9032, G9033, G903
Heart conditions	109302, 109303, 109304, 109302, 109302, 109302, 109303
Immune status	Immunosuppressed vs. immunocompetent. Immunosuppresed if most recent T-cell subset analysis report, their absolute CD4 cell count was <100 cells/µl; they had a diagnosis of either lymphoma or leukemia associated with an encounter either before the PCR test or within 60 days of the PCR test; they were on any of the following drugs on an ongoing basis, prescribed prior to the PCR test and with enough refills to include the time up to 30 days prior to the PCR test: abatacept, adalimumab, anakinra, azathioprine, basiliximab, budesonide, certolizumab, cyclosporine, daclizumab, dexamethasone, everolimus, etanercept, golimumab, infliximab, beekizumab, leflunomide, lenalidomide, methotrexate, mycophenolate, natalizumab, pomalidomide, prednisone, rituximab, secukinumab, secukinumab, torcilizumab, tofacitinib, ustekinumab, or vedolizumab. Otherwise, immunocompetent
Liver disease	ICD10 codes: [\A5145', \A5274', \B180', \B181', \B182', \B188', \B189', \B190', \B1910', \B1911', \B1921', \B1921', \B199', \B1921', \B199', \B1921', \B199', \B1921', \B199', \B1921', \B199', \B191', \B190', \B191', \B190', \B1911', \B192', \B1991', \B1921', \B199', \B221', \B581', \B581', \B500', \B501', \B510', \B511', \B510', \B511', \B500', \B700', \K700', \K700', \K7031', \K7031', \K7040', \K7041', \K709', \K715', \K7150', \K7151', \K716', \K717', \K718', \K7211', \K7220', \K7231', \K7231', \K731', \K731', \K732', \K730', \K740', \K741', \K742', \K743', \K744', \K745', \K7460', \K7469', \K771', \K751', \K754', \K7581', \K7581', \K7581', \K758', \K758', \K7581', \K758', \K759', \K751', \K758', \K759', \K751', \K758', \K759', \K759', \K759', \K759', \K761', \K762', \K763', \K766', \K766', \K766', \K768', \K7689', \K768', \K7689', \K77', \K9182', \Z944']
Mental health conditions	ICD10 codes: [F060', F061', F062', F0630', F0631', F0632', F0633', F0634', F11150', F11151', F11159', F11250', F11251', F11259', F11950', F11951', F11959', F11950', F11951', F11959', F12151', F12159', F1259',
Neighborhood income	median household income by zip code from the 2020 Census (2020 American Community Survey). URL structure (replace <zipcode> with an actual zipcode): https://api.census.gov/data/2020/acs/acs/subject?get=NAME_S1901_C01_012E&for=zip%20code%20tabulation%20area.<zipcode> . In the text that this URL will return, S1901_C01_012E is the column name for median household income</zipcode></zipcode>
Neurological disorders	ICD10 codes: [E7500, 'E7501, 'E7502, 'E7509, 'E7510, 'E7511, 'E7519, 'E7523, 'E7525, 'E7529, 'E754, 'F0151, 'F0151, 'F0280, 'F0281, 'F0391, 'F0392, 'F0391, 'F0391, 'F0391, 'F0391, 'F0391, 'F0391, 'F0391, 'F0391, 'F0391, 'F0392, 'F0393, 'F0391, 'F0392, 'F0393, 'F0391, 'F0392, 'F0393, 'F0391, 'F0392, 'F0393, 'F0391, 'F03932, 'F0393, 'F0393, 'F0393, 'F0391, 'F0392, 'F0393, 'F0391, '
Outcome	Died from COVID-19 (causal), Died with COVID-19 (incidental), Survived
Patient location	Inpatient, Outpatient, Emergency Room, or Institutional (sent from another hospital)
Peptic ulcer disease	(LU1) (2008; [K30], K31, K31, K31, K31, K33, K38, K37, K39, K37, K39, K37, K39, K20, K20, K20, K20, K20, K20, K20, K20
Peripheral vascular disease	ICD10 codes: [A5200', A5201', A5202', A5209', 1700', 1701', 170201', 170203', 170203', 170209', 170211', 170212', 170213', 170218', 170219', 170221', 170222', 170223', 170223', 170223', 170233', 170333', 170335', 170239', 170239', 170239', 170239', 170241', 170242', 170243', 170244', 170245', 170244', 170245', 170245', 170245', 170245', 170239', 170331', 170332', 170333', 170333', 170335', 170335', 170339', 170339', 170331', 170332', 170333', 170334', 170335', 170338', 170339', 170341', 17042', 170431', 170342', 170343', 170345', 170344', 170445'
Pregnancy status	Pregnant or Recently delivered, Not pregnant. (males, individuals under 13 or over 56, and recent test results excluded from results)
Pulmonany disease	ICD10 codes: [1/410', 1/411', 1/418', 1/42', 1/430', 1/431', 1/432', 1/439', 1/449', 1/449', 1/449', 1/479', 1/60', 1/61', 1/620', 1/628', 1/630', 1/631', 1/632', 1/633', 1/633', 1/635', 1/636', 1/64', 1/65', 1/662', 1/668',
Race/Ethnicity	'1670', '1671', '1672', '1675', '1675', '1675', '1676', '1679', '1684', '1701', '1703'] self-reported. Allowed values: Black. White. Hispanic. Asian + Pacific Islander. Other. + Linknown.
Remdesivir	ser topotes. nower trade, sales / mee, inspirate, sales / sale
Renal disease	ICD10 codes: ['1120', '1131', '1132', 'N183', 'N1830', 'N1831', 'N1832', 'N184', 'N185', 'N186', 'N189', 'N19', 'Z4901', 'Z4902', 'Z4931', 'Z4932', 'Z9115', 'Z940', 'Z992']
Sickle cell & thalassemia	remae vs. mae [CD10 codes: ['056',"057'']
Smoking status	Current, former, never
Substance abuse	ICD10 codes: [F1010', F1011', F10120', F10121', F10120', F10130', F10131', F10132', F10139', F1014', F10150', F10151', F10159', F10150', F10180', F10181', F10182', F10188', F1019', F1020', F10221', F10220', F10221', F10230', F10231', F10332', F10332', F10332', F10339', F1034', F10359', F10359', F10359', F10250', F10251', F10259', F1026', F1027', F10280', F10280', F10282', F10282', F10282', F1034', F10950', F10950', F10950', F1097', F10950', F1120', F1120', F11220', F11220', F11221', F11222', F11229', F1123', F1124', F1182', F11188', F1119', F11182', F11188', F1119', F1120', F1121', F11220', F11221', F11222', F11229', F1123', F1124', F11281', F11282', F11288', F119', F1120', F1121', F11220', F11221', F11222', F11229', F1223', F1124', F11281', F11282', F11288', F119', F120', F1212', F12220', F1222', F1223', F1228', F1228', F1228', F1288', F129', F13130', F13131', F13132', F13180', F1318', F1318', F1319', F1312', F13220', F13221', F13229', F1323', F1323', F1328', F1329', F13130', F13131', F13132', F13180', F13182', F13188', F1319', F1318', F1319', F1322', F13220', F13221', F13220', F13231', F13231', F13321', F13231', F13232', F13280', F1328', F1328', F1388', F1319', F1318', F1320', F1323',
	115220, '115227, '115227, '115227, '115287, '115287, '115287, '115287, '115288, '11529, '116, '116107, '116117, '116127, '1161
Tocilizumab	T15220, F15227, F15227, F15227, F15247, F15247, F15247, F15248, F15247, F15248, F1529, F161, F16107, F1617, F16127, F16128, F1619, F1627, F16287, F16287, F16287, F16287, F16287, F1629, F1627, F16107, F1617, F16127, F16127, F16187, F16187, F16187, F16287, F16287, F16287, F16287, F16287, F1627, F16177, F16127, F16127, F16187, F16187, F16187, F16187, F16187, F16187, F16187, F16187, F16287, F1927, F19127, F19127, F19130, F1917, F19180, F1917, F19287, F19297, F19287, F19287, F19287, F19297, F1927, F19287,
Tocilizumab Transplanted organ and	*15220, *15227, *15227, *15227, *15287, *15287, *15287, *15287, *15287, *15287, *15287, *1517, *15107, *16107, *16107, *16127, *161

560

562

Figure 1: Patient characteristics available for defining patient groups and subgroups

roup Reset	Vaccination Status	Ventilation Assist	Diabetes
. Cou	Vaccinated	Received ventilation assist	Known diabetes
		Did not receive ventilation assist	No reported diabetes
		Heart Conditions	Disabilities
Age	Presumed Variant	Known heart conditions	Known disabilities
30 years old	Early variants	No reported heart conditions	No reported disabilities
□ 30-60 years old	Delta	·	·
\sim >60 years old		Peripheral Vascular Disease	Renal Disease
		Known peripheral vascular	Known renal disease
Patient Location	Race/Ethnicity	disease	No reported renal disease
Inpatient	White	No reported peripheral vascular	
Outpatient	Black	disease	Cancer
Emergency room	Asian/Pacific islander		Known cancer
	Hispanic	Cerebrovascular Disease	No reported cancer
	Unknown/Other	Known cerebrovascular disease	
BMI		No reported cerebrovascular	Acquired Immunodeficiency
Underweight	Pregnancy Status	disease	Syndrome
Healthy weight	Pregnant		Known acquired
Overweight	Not pregnant	Neurological Disorders	immunodeficiency syndrome
Obese		Known neurological disorders	No reported acquired
	Outcome	No reported neurological	immunodeficiency syndrome
Immune Status	Survived	disorders	
Immunosuppressed	Died from COVID-19 (causal)		Substance Abuse
Immunocompetent	Died with COVID-19 (incidental) Delimonary Disease	Known substance abuse
		Known pulmonary disease	No reported substance abuse
Smoking Status	Blood Products	No reported pulmonary disease	🗆 Mantal Haakk Canditiana
Current smokers	Received blood products		Mental Health Conditions
Former smokers	Did not receive blood products		Known mental health Ne reported mental health
Never smoked			
		disease	conditions
Presentation	 Received dexametnasone Diduct maximum development 	No reported connective tissue	Sickle Cell & Thalassemia
Sick-appearing	 Did not receive dexamethasone 	disease	Known sickle cell & thalassem
Well-appearing	Bemdesivir	Pentic Illcer	
			thalassomia
Neighborhood Income	Did pot receive remdesivir	No reported poptic ulcor	ulalassellila
□ <\$52,000		 No reported peptic dicer 	Transplanted Organ And Tissue
	Tocilizumab	Liver Disease	Status
	Received tocilizumab	Known liver disease	Known transplanted organ and
	Did not receive tocilizumab	No reported liver disease	tissue status
□ >\$130,000			
			and tissue status
			and lissue status

Figure 2: Overall bimodal distribution of viral loads





566 Figure 3: Viral load comparisons by remdesivir treatment, patient presentation, and outcome

568 Figure 4: Antigen test results from head-to-head trial and performance on patient subgroups



570 Figure 5: Determination of the contagiousness threshold for omicron-era SARS-CoV-2 strains





Figure 6: Sequencing late-2022 strain and generalizability of Massachusetts-level results to the

575 **References**

- 576 1. National Research Council, Division on Earth and Life Studies, Board on Life Sciences,
- 577 Committee on a Framework for Developing a New Taxonomy of Disease (2011). Toward
- 578 Precision Medicine: Building a Knowledge Network for Biomedical Research and a New
- 579 Taxonomy of Disease (National Academies Press).
- Arnaout, R., Lee, R.A., Lee, G.R., Callahan, C., Cheng, A., Yen, C.F., Smith, K.P., Arora, R., and
 Kirby, J.E. (2021). The Limit of Detection Matters: The Case for Benchmarking Severe Acute
 Respiratory Syndrome Coronavirus 2 Testing. Clin Infect Dis. 10.1093/cid/ciaa1382.
- Wild, D. ed. (2013). The immunoassay handbook: theory and applications of ligand binding,
 ELISA, and related techniques 4th ed. (Elsevier).
- Hill, E.D., Yilmaz, F., Callahan, C., Cheng, A., Braun, J., and Arnaout, R. (2022). *ct2vl* :
 Converting Ct Values to Viral Loads for SARS-CoV-2 RT-qPCR Test Results (Microbiology)
 10.1101/2022.06.20.496929.

Callahan Cody, Lee Rose A., Lee Ghee Rye, Zulauf Kate, Kirby James E., Arnaout Ramy, and
 Miller Melissa B. Nasal Swab Performance by Collection Timing, Procedure, and Method of
 Transport for Patients with SARS-CoV-2. Journal of Clinical Microbiology *59*, e00569-21.
 10.1128/JCM.00569-21.

592 6. Callahan, C., Ditelberg, S., Dutta, S., Littlehale, N., Cheng, A., Kupczewski, K., McVay, D.,

593 Riedel, S., Kirby, J.E., and Arnaout, R. (2021). Saliva is Comparable to Nasopharyngeal Swabs

for Molecular Detection of SARS-CoV-2. Microbiol Spectr *9*, e0016221.

595 10.1128/Spectrum.00162-21.

Pilarowski, G., Lebel, P., Sunshine, S., Liu, J., Crawford, E., Marquez, C., Rubio, L., Chamie, G.,
 Martinez, J., Peng, J., et al. (2021). Performance Characteristics of a Rapid Severe Acute
 Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site
 in San Francisco. J Infect Dis 223, 1139–1144. 10.1093/infdis/jiaa802.

8. Mina, M.J., Parker, R., and Larremore, D.B. (2020). Rethinking Covid-19 Test Sensitivity - A
Strategy for Containment. N Engl J Med *383*, e120. 10.1056/NEJMp2025631.

9. Stanley, S., Hamel, D.J., Wolf, I.D., Riedel, S., Dutta, S., Contreras, E., Callahan, C.J., Cheng,

A., Arnaout, R., Kirby, J.E., et al. (2022). Limit of Detection for Rapid Antigen Testing of the

604 SARS-CoV-2 Omicron and Delta Variants of Concern Using Live-Virus Culture. J Clin

605 Microbiol *60*, e00140-22. 10.1128/jcm.00140-22.

10. Kirby, J.E., Riedel, S., Dutta, S., Arnaout, R., Cheng, A., Ditelberg, S., Hamel, D.J., Chang, C.A.,

and Kanki, P.J. (2022). SARS-CoV-2 Antigen Tests Predict Infectivity based on viral culture:

608 comparison of antigen, PCR viral load, and viral culture testing on a large Sample Cohort.

609 Clinical Microbiology and Infection, S1198743X22003743. 10.1016/j.cmi.2022.07.010.

610 11. Charlson, M.E., Pompei, P., Ales, K.L., and MacKenzie, C.R. (1987). A new method of

classifying prognostic comorbidity in longitudinal studies: development and validation. J
Chronic Dis 40, 373–383. 10.1016/0021-9681(87)90171-8.

613 12. Greenberg, J.A., Hohmann, S.F., Hall, J.B., Kress, J.P., and David, M.Z. (2016). Validation of a
614 Method to Identify Immunocompromised Patients with Severe Sepsis in Administrative
615 Databases. Annals ATS *13*, 253–258. 10.1513/AnnalsATS.201507-415BC.

616 13. Knight, S.R., Ho, A., Pius, R., Buchan, I., Carson, G., Drake, T.M., Dunning, J., Fairfield, C.J.,

617 Gamble, C., Green, C.A., et al. (2020). Risk stratification of patients admitted to hospital

618 with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and 619 validation of the 4C Mortality Score. BMJ *370*, m3339. 10.1136/bmj.m3339.

620 14. Elixhauser, A., Steiner, C., Harris, D.R., and Coffey, R.M. (1998). Comorbidity measures for

- 621 use with administrative data. Med Care *36*, 8–27. 10.1097/00005650-199801000-00004.
- 622 15. Shain, E.B., and Clemens, J.M. (2008). A new method for robust quantitative and qualitative
 623 analysis of real-time PCR. Nucleic Acids Res *36*, e91. 10.1093/nar/gkn408.

- 624 16. Kirby, J.E., Cheng, A., Cleveland, M.H., Degli-Angeli, E., DeMarco, C.T., Faron, M., Gallagher,
- 625 T., Garlick, R.K., Goecker, E., Coombs, R.W., et al. (2022). A Multi-Institutional Study
- 626 Benchmarking Cycle Threshold Values for Major Clinical SARS-CoV-2 RT-PCR Assays.
- 627 2022.06.22.22276072. 10.1101/2022.06.22.22276072.
- 628 17. CoVariants https://covariants.org/.
- 18. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M.,
 Prettenhofer, P., Weiss, R., Dubourg, V., et al. (2011). Scikit-learn: Machine Learning in
- 631 Python. Journal of Machine Learning Research *12*, 2825–2830.
- 632 19. Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer,
- D., Jones, T.C., Vollmar, P., Rothe, C., et al. (2020). Virological assessment of hospitalized
 patients with COVID-2019. Nature *581*, 465–469. 10.1038/s41586-020-2196-x.
- 635 20. La Scola, B., Le Bideau, M., Andreani, J., Hoang, V.T., Grimaldier, C., Colson, P., Gautret, P.,
- and Raoult, D. (2020). Viral RNA load as determined by cell culture as a management tool
- 637 for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol
- 638 Infect Dis *39*, 1059–1061. 10.1007/s10096-020-03913-9.
- 639 21. Huang, C.-G., Lee, K.-M., Hsiao, M.-J., Yang, S.-L., Huang, P.-N., Gong, Y.-N., Hsieh, T.-H.,
- 640 Huang, P.-W., Lin, Y.-J., Liu, Y.-C., et al. (2020). Culture-Based Virus Isolation To Evaluate
- Potential Infectivity of Clinical Specimens Tested for COVID-19. J Clin Microbiol *58*, e0106820. 10.1128/JCM.01068-20.
- 643 22. Artic Network https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html.
- 644 23. Quick, J., Grubaugh, N.D., Pullan, S.T., Claro, I.M., Smith, A.D., Gangavarapu, K., Oliveira, G.,
- 645 Robles-Sikisaka, R., Rogers, T.F., Beutler, N.A., et al. (2017). Multiplex PCR method for
- 646 MinION and Illumina sequencing of Zika and other virus genomes directly from clinical
- 647 samples. Nat Protoc 12, 1261–1276. 10.1038/nprot.2017.066.

040 - 24, Haulielu, J., Megili, C., Dell, J.M., Huuulestoli, J., Fotter, D., Callender, C., Jaguleliku	648	24. Hadfield. J.	Megill. C., Bell	. S.M., Huddleston.	J., Potter, B.	. Callender. C	C., Sagulenko,
--	-----	------------------	------------------	---------------------	----------------	----------------	----------------

649 Bedford, T., and Neher, R.A. (2018). Nextstrain: real-time tracking of pathogen evolution.

650 Bioinformatics *34*, 4121–4123. 10.1093/bioinformatics/bty407.

- 25. Pratt, J.W., and Gibbons, J.D. Concepts of nonparametric theory (Springer InternationalPublishing).
- 26. Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
 Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B
 (Methodological) 57, 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x.
- 656 27. Tukey, J. (1953). Multiple Comparisons. J. Am. Stat. Assoc. 48, 624–625.
- 657 28. Morgan, A. COVIRAL webapp back-end. https://github.com/chhotii-alex/antigen-flask.
- 658 29. Morgan, A. COVIRAL webapp front-end. https://github.com/chhotii-alex/antigen-sensitivity.
- 30. Lamb, Y.N. (2020). Remdesivir: First Approval. Drugs *80*, 1355–1363. 10.1007/s40265-02001378-w.

31. Ahmed, A., Song, Y., and Wadhera, R.K. (2022). Racial/Ethnic Disparities in Delaying or Not
Receiving Medical Care During the COVID-19 Pandemic. J GEN INTERN MED *37*, 1341–1343.
10.1007/s11606-022-07406-7.

32. Watson, C. (2022). Rise of the preprint: how rapid data sharing during COVID-19 has
changed science forever. Nature Medicine 28, 2–5. 10.1038/s41591-021-01654-6.

- 33. Rando, H.M., Boca, S.M., McGowan, L.D., Himmelstein, D.S., Robson, M.P., Rubinetti, V.,
- Velazquez, R., Greene, C.S., and Gitter, A. (2021). An Open-Publishing Response to the
 COVID-19 Infodemic. CEUR Workshop Proc *2976*, 29–38.
- 34. Ross, J.S. (2021). Covid-19, open science, and the CVD-COVID-UK initiative. BMJ *373*, n898.
 10.1136/bmj.n898.

- 671 35. Callahan, C.J., Lee, R., Zulauf, K.E., Tamburello, L., Smith, K.P., Previtera, J., Cheng, A., Green,
- A., Azim, A.A., Yano, A., et al. (2020). Open Development and Clinical Validation Of Multiple
- 3D-Printed Nasopharyngeal Collection Swabs: Rapid Resolution of a Critical COVID-19
- Testing Bottleneck. J Clin Microbiol, JCM.00876-20, jcm; JCM.00876-20v1.
- 675 10.1128/JCM.00876-20.
- 36. Arnaout, R.A. (2021). Cooperation under Pressure: Lessons from the COVID-19 Swab Crisis.
 Journal of Clinical Microbiology *59*, e01239-21. 10.1128/JCM.01239-21.
- 678 37. Tse, E.G., Klug, D.M., and Todd, M.H. (2020). Open science approaches to COVID-19.
- 679 F1000Res *9*, 1043. 10.12688/f1000research.26084.1.
- 38. Perillat, L., and Baigrie, B.S. (2021). COVID-19 and the generation of novel scientific
 knowledge: Evidence-based decisions and data sharing. J Eval Clin Pract 27, 708–715.
 10.1111/jep.13548.
- 683 39. Li, R., von Isenburg, M., Levenstein, M., Neumann, S., Wood, J., and Sim, I. (2021). COVID-19
- trials: declarations of data sharing intentions at trial registration and at publication. Trials
 22, 153. 10.1186/s13063-021-05104-z.
- 40. Gardener, A.D., Hick, E.J., Jacklin, C., Tan, G., Cashin, A.G., Lee, H., Nunan, D., Toomey, E.C.,
- and Richards, G.C. (2022). Open science and conflict of interest policies of medical and
- 688 health sciences journals before and during the COVID-19 pandemic: A repeat cross-
- 689 sectional study: Open science policies of medical journals. JRSM Open 13,
- 690 20542704221132139. 10.1177/20542704221132139.
- 691 41. Besançon, L., Peiffer-Smadja, N., Segalas, C., Jiang, H., Masuzzo, P., Smout, C., Billy, E.,
- Deforet, M., and Leyrat, C. (2021). Open science saves lives: lessons from the COVID-19
 pandemic. BMC Med Res Methodol *21*, 117. 10.1186/s12874-021-01304-y.
- 42. Wood, A., Denholm, R., Hollings, S., Cooper, J., Ip, S., Walker, V., Denaxas, S., Akbari, A.,
 Banerjee, A., Whiteley, W., et al. (2021). Linked electronic health records for research on a

696 nationwide cohort of more than 54 million people in England: data resource. BMJ *373*,
697 n826. 10.1136/bmj.n826.

- 43. Rao, S.N., Manissero, D., Steele, V.R., and Pareja, J. (2020). A Systematic Review of the
 Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther *9*, 573–
 586. 10.1007/s40121-020-00324-3.
- 44. Satlin, M.J., Chen, L., Gomez-Simmonds, A., Marino, J., Weston, G., Bhowmick, T., Seo, S.K.,
 Sperber, S.J., Kim, A.C., Eilertson, B., et al. (2022). Impact of a Rapid Molecular Test for
 Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After
 Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Clinical Infectious Diseases
 705 75, 2066–2075. 10.1093/cid/ciac354.
- 45. Savela, E.S., Viloria Winnett, A., Romano, A.E., Porter, M.K., Shelby, N., Akana, R., Ji, J.,
 Cooper, M.M., Schlenker, N.W., Reyes, J.A., et al. (2022). Quantitative SARS-CoV-2 ViralLoad Curves in Paired Saliva Samples and Nasal Swabs Inform Appropriate Respiratory
 Sampling Site and Analytical Test Sensitivity Required for Earliest Viral Detection. J Clin
 Microbiol *60*, e0178521. 10.1128/JCM.01785-21.
- 711 46. Viloria Winnett, A., Porter, M.K., Romano, A.E., Savela, E.S., Akana, R., Shelby, N., Reyes,
- J.A., Schlenker, N.W., Cooper, M.M., Carter, A.M., et al. (2022). Morning SARS-CoV-2
- 713 Testing Yields Better Detection of Infection Due to Higher Viral Loads in Saliva and Nasal
- 514 Swabs upon Waking. Microbiol Spectr *10*, e0387322. 10.1128/spectrum.03873-22.
- 47. Brümmer, L.E., Katzenschlager, S., Gaeddert, M., Erdmann, C., Schmitz, S., Bota, M., Grilli,
- 716 M., Larmann, J., Weigand, M.A., Pollock, N.R., et al. (2021). Accuracy of novel antigen rapid
- 717 diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med 18,
- 718 e1003735. 10.1371/journal.pmed.1003735.
- 48. Lee, R.A., Herigon, J.C., Benedetti, A., Pollock, N.R., and Denkinger, C.M. (2021).
- 720 Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular

- 721 Detection: A Systematic Review and Meta-analysis. Journal of Clinical Microbiology.
- 722 10.1128/JCM.02881-20.
- 49. El Emam, K. (2013). Guide to the de-Identification of Personal Health Information (Auerbach
- 724 Publishers, Incorporated).
- 50. El Emam, K., Rodgers, S., and Malin, B. (2015). Anonymising and sharing individual patient
- 726 data. BMJ *350*, h1139. 10.1136/bmj.h1139.